Curia’s Post

We summarized the clinical evidence for the Value of Platelets Rich Plasma Injections. https://lnkd.in/grmwgY8T

Data on CDK4/6 inhibitors in adjuvant setting in early HR+/HER2-#breastcancer looks promising. Sharing an article that puts trials data into clinical practice perspective, suggesting how to choose wisely between CDK4/6i.

Exciting developments in MS treatments as the EU has approved Genentech's new twice-yearly injection for multiple sclerosis patients, promising greater convenience and an element of freedom! 💉 This revolutionary anti-CD20 therapy, OCREVUS® (ocrelizumab), offers the same dosing schedule as the existing intravenous (IV) option but comes in a 10-minute injection. No more IVs needed—huge for patient quality of life! ✅ Clinical trials of OCREVUS have shown a relapse suppression rate of over 97% in a year. Authorisation of this treatment for the central nervous system autoimmune condition in the EU is based on data from the Phase III OCARINA II trial. That's remarkable progress for those battling relapsing and primary progressive MS 🙏 #Genentech #Roche #MultipleSclerosis #MS #AutoImmune #Innovation #Healthcare #Biotechnology #ClinicalTrialSuccess #ClinicalResearch #EUApproved #LifeScience #ElixirAssociates #StaffingPartner

https://bit.ly/45sSPGQ AL Amyloidosis is a blood desease that is crucial the early diagnosis. Before those patients werent treated whith the same dugs as MM ( Myeloma Múltiple), and nowadays we can afford only one approuved drug, in some countries whith difficulties to get out. Prothena is leading for a drug in Pase III giving to us one more option for ouers patients. #AL #ClinicalTrials #Prothena #SomosAmilo www.amilo.es

https://bit.ly/45sSPGQ AL Amyloidosis is a blood desease that is crucial the early diagnosis. Before those patients werent treated whith the same dugs as MM ( Myeloma Múltiple), and nowadays we can afford only one approuved drug, in some countries whith difficulties to get out. Prothena is leading for a drug in Pase III giving to us one more option for ouers patients. #AL #ClinicalTrials #Prothena #SomosAmilo www.amilo.es

This excellent paper revealed an interesting CD4+ T cells response upon combination of antibodies therapy (PD-L1+CTLA-4) in 20 HNSCC patients. Looking forward to seeing the efficacy of this trial in a longer time window (NCT03784066, https://lnkd.in/ggZsrpmy) 😉😉 https://lnkd.in/gu-nwFph

Various venetoclax-based therapies were studied to evaluate their effectiveness as a first treatment option for CLL. https://bit.ly/4cJ46oN

Thoughts on A New Era in Radioligand Therapy (RLT) The recent acquisitions of RayzeBio by Bristol Myers Squibb and POINT Biopharma by Eli Lilly mark significant milestones in the radioligand therapy (RLT) sector, highlighting the shift towards personalized cancer treatments. BMS's $4.1 billion deal for RayzeBio brings a leading actinium-based platform to its oncology lineup, with RayzeBio's RYZ101 targeting various cancers. This enhances BMS's solid tumor therapy options and positions it as a key player in the RLT field. Meanwhile, Lilly's purchase of POINT Biopharma underscores its investment in advancing radioligand therapies, intensifying competition with RLT leader Novartis. Novartis, a pioneer in RLT, faces increased rivalry from these strategic moves. At the JP Morgan Healthcare Conference, CEO Vas Narasimhan emphasized RLT's advantages over Antibody-Drug Conjugates (ADCs) due to their efficacy and lower toxicity, highlighting Novartis's focus on expanding its RLT research and manufacturing. These developments signal a growing competitive landscape in RLT, promising more precise and effective cancer treatments. As professionals in the oncology and pharmaceutical sectors, it's an exciting time to be part of this transformative journey. The advancements in RLT are a testament to our collective pursuit of groundbreaking solutions to combat cancer more effectively. https://lnkd.in/eSkk62hH #Oncology #RadioligandTherapy #PharmaceuticalInnovation #BMS #EliLilly #Novartis #CancerCare RLT from Novartis (Youtube)

Gene&Cell Therapy >> Umoja to dose first patient with in vivo CAR-T by end of this year: Umoja Biopharma has the FDA’s green light to dose the first patient with what it believes could be a more readily accessible CAR-T therapy. The company has plans to launch a Phase 1 trial this year for UB-VV111, its experimental in vivo gene therapy for blood cancer. Unlike ex vivo CAR-Ts on the market, in vivo treatments wouldn’t require the costly and time-consuming process of collecting cells, engineering them, and then delivering them back to the patient. Umoja’s VivoVec platform instead seeks to help the body make its own cancer-killing CAR-T cells. David Fontana “Every step of the CAR-T process today loses patients to the burdens and complexity — patients that will lose out on the oftentimes curative potential of CAR-Ts,” Umoja COO David Fontana told Endpoints News. “We view those losses along the treatment journey ultimately as efficacy failures for the CAR-T industry. We are motivated to simplify all of this with our VivoVec-driven in vivo approach.” AbbVie took interest in the idea earlier this year when it agreed to pay an undisclosed upfront and equity investment plus up to $1.44 billion in milestones for an option to license UB-VV111 and develop other in vivo CAR-Ts with Umoja. Pharmaceutical companies large and small are developing in vivo cell therapies, including Moderna, Capstan Therapeutics, Myeloid Therapeutics and Interius BioTherapeutics, which got clearance to launch an in-human trial in Australia earlier this month. Umoja’s trial will enroll patients with relapsed or refractory large B cell lymphoma and chronic lymphocytic leukemia. “We hope there is a paradigm shift in the management of blood cancer patients, where CAR-T cells can truly be used in a broader patient population,” Fontana said. “No apheresis. No months wait to secure a manufacturing slot and have a patient’s cell manufactured. No cost and complexity of the ex vivo process today.” #lucidquest #genetherapy #celltherapy

At Cartesian, we're proud to be developing Descartes-08, the first mRNA CAR T-cell therapy for #autoimmunediseases, in #Lupus and other indications. Learn more about how we’re expanding the reach of #celltherapy to autoimmunity: https://bit.ly/3Qr2LdY #WorldLupusDay